US Stock MarketDetailed Quotes

PLUR Pluri Inc

Watchlist
  • 5.6480
  • +0.0352+0.63%
Close Jul 26 16:00 ET
  • 5.6480
  • 0.00000.00%
Post 20:01 ET
30.44MMarket Cap-1370P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Jul 18 01:33
    NEWS
    $Pluri Inc(PLUR.US)$ $
    Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
    Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division.
    PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment.
    This collaboration leverages Pluri's 47,000 square foot GMP cell production facility a...
    Trytosaveabit
    Trytosaveabit
    Jun 6 05:52
    Update
    $Pluri Inc(PLUR.US)$ Pluri Says US NIAID Will Provide Company With $1.4M From July 1, 2024 To June 30, 2025; NIAID Exercised Its Option For Year Two Of The Three-year $4.2M Contract It Entered Into With Pluri In July 2023
    Benzinga· just
    The company will manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).
    Trytosaveabit
    Trytosaveabit
    May 20 06:13
    Hmm? Update!
    $Pluri Inc(PLUR.US)$ Benzinga· 2 mins ago
    Pluri Collaborated With Wilk Technologies To Develop Human Breast Milk-derived Food Production On A Commercial Scale
    Jaguar8
    Jaguar8
    May 2 06:06
    $Pluri Inc(PLUR.US)$
    NEWS
    Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
    Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 ...
    Trytosaveabit
    Trytosaveabit
    Apr 17 06:03
    Update
    $Pluri Inc(PLUR.US)$ Pluri Inc: on April 15, Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq Listing Rule 5550(a)(2)
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg